Tezosentan in the Treatment of Acute Heart Failure

PHASE3CompletedINTERVENTIONAL
Enrollment

713

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Acute Heart FailureAcute Decompensation of Chronic Heart FailureNew Onset of Heart Failure
Interventions
DRUG

tezosentan

tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)

DRUG

placebo

Trial Locations (42)

Unknown

Oracle Research, Huntsville

USC Medical Center, Los Angeles

Jacksonville Center for Clinical Research, Jacksonville

University of Miami-Jackson Memorial Hospital, Miami

University Hospital, Augusta

University of Iowa Hospital and Clinics, Iowa City

Medical Research Institute, Slidell

Baystate Medical Center-Cardiology Section, Springfield

Elmhurst Hospital Center, Elmhurst

Columbia Presbyterian Medical Center-Heart Failure Center, New York

New York University School of Medicine, New York

University of North Carolina, Chapel Hill

Duke University Medical Center, Durham

LeBauer Cardiovascular Research Foundation, Greensboro

Baylor College of Medicine - Texas Medical Center, Houston

University of Texas, MD Anderson Cancer Center, Houston

Alfred Hospital, Monash University, Central and Eastern School, Prahran

Concord Repatriation Hospital, Concord NSW

Queen Elizabeth Hospital, Woodville SA

Faculty Hospital St. Anna, Brno

Klinika Kardiologie IKEM, Prague

University Hospital Vinohrady (FNKV), Prague

Masaryk Hospital, Ústí nad Labem

Universitatsklinikum der Humboldt-Universitat Berlin, Campus Charite Mitte, Med. Klinik und Poliklinik, Kardiologie, Berlin

Universitat Greifswald, Klinik fur Innere Medizin B, Greifswald

Asklepios Klinik Langen, Abteilung fur Innere Medizin, Langen

Universitatsklinikum Schleswig Holstein, Medizinische Klinik II, Kardiologie, Lübeck

Klinik u. Poliklinik F. Inn. Med. II, Univ. Klinik Regensburg, Regensburg

Jahn Ferenc, Delpesti Korhaz, Budapest

Polyclinic of the Hospitaler Brothers of St. John of God, Budapest

University of Debrecen, Debrecen

2nd Department of Medicine & Cardiology Centre, Szeged

Cattedra di Cardiologia, c/o Spedali Civili, Brescia

Istituto Clinico Humanitas, U.O. Cardiologia Clin. E Insuff. Cardiaca, Rozzano (MI)

Sentralsykehuset i More og Romsdal, Dept. of Cardiology, Ålesund

Aker University Hospital, Div. Cardiology, Oslo

Central Hospital in Rogaland, Cardiology Division, Stavanger

University Department of Medicine, City Hospital, Birmingham

Cardiology Department, Bridlington & District Hospital, Bridlington

University of Glasgow West, Glasgow

Dept. of Medicine & Therapeutics, University of Leicester, Leicester

Husova 10

Krajska Nemocnice Liberec, Liberec

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT00524433 - Tezosentan in the Treatment of Acute Heart Failure | Biotech Hunter | Biotech Hunter